Cathie Wood is making a massive bet on gene editing, pouring $5.4 billion into companies like Beam Therapeutics while selling ...

Clinical laboratory professionals are transforming healthcare for expectant mothers and their babies, according to the special January issue of Clinical Chemistry published by the Association for ...

Tiny, sun-powered organisms found in freshwater pools could soon fuel Hawaiʻi’s sustainable future, according to researchers ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $93 and keeps a Buy rating on the shares.

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen ...

Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines. Through its partnerships, the Genetic Medicines division is ...

Zebrafish (Danio Rerio) have emerged as a powerful bioengineering platform for next-generation drug discovery, offering an unparalleled combination of ...

Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

In a first for the UAE, the Yas Clinic in Khalifa City, working with the Abu Dhabi Stem Cells Centre and Vertex ...

Looking back at the performance of ARK Invest, led by Cathie Wood (“Cathie Wood”), in 2025, despite reducing its holdings of Tesla (TSLA) by over 633,000 shares during the ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class, cancer medicines, today announced that ...